Vyriad Expands Clinical Study of Oncolytic Virus Therapy in Bladder Cancer Patients ROCHESTER, Minn., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vyriad, Inc. announced today the addition of new clinical sites in its ongoing clinical study evaluating an intravesical oncolytic measles virus...

Imanis Life Sciences to Present IMMUNO-COV, a First-in-Class Neutralizing Antibody Test for COVID-19, at American Society of Gene and Cell Therapy Symposium High-throughput clinical assay detects, quantifies SARS-CoV-2-neutralizing antibodies Imanis Life Sciences is an affiliate of Vyriad Inc. ROCHESTER, Minn., Sept. 14, 2020 (GLOBE NEWSWIRE) --...

Vyriad Announces Initiation of Phase 2 Trial in Multiple Cancer Indications ROCHESTER, Minn., July 20, 2020 (GLOBE NEWSWIRE) -- Vyriad, Inc. announced today the dosing of the first patient in a Phase 2 clinical trial to evaluate its investigational oncolytic virus...

Vyriad Inc. to Present Clinical Trial Updates for its Oncolytic Virotherapies at Virtual 2020 ASCO Annual Meeting ROCHESTER, Minn., May 29, 2020 (GLOBE NEWSWIRE) -- Vyriad, Inc. announced today that it will present data and information about the design of clinical trials evaluating its oncolytic viruses at the...

Vyriad Inc. Announces Development of a New Antibody Test to Determine Protective Immunity From COVID-19 Vyriad test detects SARS-CoV-2 virus-neutralizing antibodies Developed as part of an ongoing collaboration with Regeneron ROCHESTER, Minn., May 12, 2020 (GLOBE NEWSWIRE) -- Vyriad, Inc. announced...